News und Analysen
![Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2019](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2019
Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the fourth quarter and fiscal year 2019.
Fourth quarter 2019 results:
-
Revenue of $953 million, a 10% increase compared
![Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2019](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2019
Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the fourth quarter and fiscal year 2019.
Fourth quarter 2019 results:
-
Revenue of $953 million, a 10% increase compared
![Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2019](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2019
Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the fourth quarter and fiscal year 2019.
Fourth quarter 2019 results:
-
Revenue of $953 million, a 10% increase compared
![Pulmatrix: Wann folgt die Explosion 2.0?](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Pulmatrix: Wann folgt die Explosion 2.0?
Mit einem Schlusskurs von 1,78 USD markierte die Aktie von Pulmatrix (WKN: A2PD3T) gestern ein neues Langzeithoch. Obwohl NBC-Mitglieder auch hier bereits auf teilweise über +100% Gewinn sitzen
![Agilent Technologies to Webcast First Quarter Fiscal Year 2020 Financial Results Conference Call](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Agilent Technologies to Webcast First Quarter Fiscal Year 2020 Financial Results Conference Call
Agilent Technologies, Inc. (NYSE: A) will release first-quarter fiscal year 2020 financial results after the stock market closes on Feb. 18. The company will also host a live webcast of its
![Quidel to Hold Fourth Quarter and Full Year 2019 Financial Results Conference Call on February 12th, 2020](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Quidel to Hold Fourth Quarter and Full Year 2019 Financial Results Conference Call on February 12th, 2020
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report fourth quarter and full year 2019
![Acceleron Pharma: Bluthochdruck!](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Acceleron Pharma: Bluthochdruck!
Die Aktie von Acceleron Pharma (WKN: A1W5LE) gehört heute zu den ganz großen Gewinnern am US-Aktienmarkt und kann um sage und schreibe mehr als +50% zulegen.
Dabei handelt es sich bei Acceleron
![LivaNova to Host Conference Call for Fourth Quarter and Full-Year 2019 Results](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
LivaNova to Host Conference Call for Fourth Quarter and Full-Year 2019 Results
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its fourth quarter and full-year 2019 results on Wednesday, Feb. 26
![CommonSpirit Health Chooses Premier Inc. to Clinically Integrate its Newly Merged Supply Chain](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
CommonSpirit Health Chooses Premier Inc. to Clinically Integrate its Newly Merged Supply Chain
CommonSpirit Health will be partnering with Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, to achieve operational excellence as it undergoes the complex integration of its
![PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2019 RESULTS](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2019 RESULTS
Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter and full-year 2019 and provided 2020 financial guidance.
Results for the fourth quarter and the full year of 2019 and 2018(7)
![PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2019 RESULTS](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2019 RESULTS
Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter and full-year 2019 and provided 2020 financial guidance.
Results for the fourth quarter and the full year of 2019 and 2018(7)
![Agilent Introduces New Cutting-Edge SureSelect DNA Kit](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Agilent Introduces New Cutting-Edge SureSelect DNA Kit
Agilent Technologies Inc. (NYSE: A) today introduced a new product designed to address key challenges that laboratories encounter when preparing DNA sequencing libraries for their research. The new
![EOS imaging: Information Relating to the Total Number of Share Capital and Voting Rights](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
EOS imaging: Information Relating to the Total Number of Share Capital and Voting Rights
Regulatory News:
EOS imaging (Paris:EOSI) (Euronext, FR0011191766 - EOSI - Eligible PEA - PME), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and
![Mauna Kea Technologies Receives FDA 510(k) Clearance of Cellvizio® with a Fluorescent Dye, Fluorescein, as Drug Device Combination](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Mauna Kea Technologies Receives FDA 510(k) Clearance of Cellvizio® with a Fluorescent Dye, Fluorescein, as Drug Device Combination
Regulatory News:
Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) (Euronext: MKEA), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (pCLE/nCLE)
![Humana Foundation Investing $7.6 Million in Eight Communities to Address Social Determinants of Health](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Humana Foundation Investing $7.6 Million in Eight Communities to Address Social Determinants of Health
The Humana Foundation, philanthropic arm of Humana Inc. (NYSE: HUM) for the past 38 years, is investing $7.6 million in eight communities across the southeastern United States to address social
![Lantheus Holdings Announces Senior Leadership Appointment](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Lantheus Holdings Announces Senior Leadership Appointment
Lantheus Holdings, Inc. (NASDAQ: LNTH) (“Lantheus”), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a leader in the development, manufacture and commercialization of innovative
![Trevena mit +50% in 7 Wochen - NBC erneut mit Volltreffer-Timing!](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Trevena mit +50% in 7 Wochen - NBC erneut mit Volltreffer-Timing!
Während die Börsen derzeit eine Verschnaufpause einlegen und der für den No Brainer Club besonders relevante NASDAQ Biotechnology Index wieder nahe Jahrestief notiert, kennt unsere Empfehlung des
![Lysogene Announces Its Corporate Agenda For 2020](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Lysogene Announces Its Corporate Agenda For 2020
Regulatory News:
Lysogene (Paris:LYS) (FR0013233475 – LYS) today announced its corporate agenda* for 2020:
17 February 2020:
Sales and cash position at the end of 2019
20 March
![Pfizer Vaccines Launches Global Centers of Excellence Network to Conduct Real-World Research on Vaccine-Preventable Diseases Affecting Adults](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Pfizer Vaccines Launches Global Centers of Excellence Network to Conduct Real-World Research on Vaccine-Preventable Diseases Affecting Adults
Pfizer Inc. (NYSE: PFE) announced today the launch of its Vaccines Division’s Centers of Excellence Network, a global program of collaborations with academic institutions to conduct real-world
![Pfizer Vaccines Launches Global Centers of Excellence Network to Conduct Real-World Research on Vaccine-Preventable Diseases Affecting Adults](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Pfizer Vaccines Launches Global Centers of Excellence Network to Conduct Real-World Research on Vaccine-Preventable Diseases Affecting Adults
Pfizer Inc. (NYSE: PFE) announced today the launch of its Vaccines Division’s Centers of Excellence Network, a global program of collaborations with academic institutions to conduct real-world
![Agilent Announces CrossLab Group Leadership Transition](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Agilent Announces CrossLab Group Leadership Transition
Agilent Technologies Inc. (NYSE: A) today announced that Mark Doak, Agilent senior vice president and president of the Agilent CrossLab Group, has decided to retire on May 1, 2020. The company has
![Eine neu veröffentlichte multizentrische RCT zeigt, dass Smith+Nephew PICO◊ sNPWT kanisterlose Unterdruck-Wundtherapie herkömmlicher tNPWT bei der Reduzierung von Wundfläche, -tiefe und -volumen bei DFU und UCV überlegen ist](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Eine neu veröffentlichte multizentrische RCT zeigt, dass Smith+Nephew PICO◊ sNPWT kanisterlose Unterdruck-Wundtherapie herkömmlicher tNPWT bei der Reduzierung von Wundfläche, -tiefe und -volumen bei DFU und UCV überlegen ist
Smith+Nephew (LSE:SN, NYSE:SNN), das globale Medizintechnikunternehmen, freut sich, die Veröffentlichung von Ergebnissen aus einer neuen randomisierten kontrollierten klinischen Studie (RCT)
![Pfizer’s Greenstone and Digital Men’s Health Clinic Roman Collaborate to Offer Patients Remote Access to the Only FDA-Approved Authorized Generic Version of Viagra® (sildenafil citrate)](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Pfizer’s Greenstone and Digital Men’s Health Clinic Roman Collaborate to Offer Patients Remote Access to the Only FDA-Approved Authorized Generic Version of Viagra® (sildenafil citrate)
Greenstone, Upjohn’s U.S.-based generics business and a wholly owned subsidiary of Pfizer Inc., and Roman, an innovative digital healthcare clinic for men, today announced a supply agreement to
![Pfizer’s Greenstone and Digital Men’s Health Clinic Roman Collaborate to Offer Patients Remote Access to the Only FDA-Approved Authorized Generic Version of Viagra® (sildenafil citrate)](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Pfizer’s Greenstone and Digital Men’s Health Clinic Roman Collaborate to Offer Patients Remote Access to the Only FDA-Approved Authorized Generic Version of Viagra® (sildenafil citrate)
Greenstone, Upjohn’s U.S.-based generics business and a wholly owned subsidiary of Pfizer Inc., and Roman, an innovative digital healthcare clinic for men, today announced a supply agreement to
![Evotec: Neue Top-Allianz – Anleger im Glück](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Evotec: Neue Top-Allianz – Anleger im Glück
Der News-Reigen setzt sich fort: Mit der auf Krebstherapien spezialisierten Indivumed initiiert Evotec (WKN: 566480) eine zweite Forschungsallianz, wie der TecDAX-Konzern heute mitteilt.
Konkret